Abivax Shares Rebound After Ulcerative Colitis Data, but Safety Overhang Keeps Analysts at Odds
05.06.2026 - 18:56:51 | boerse-global.de
The week following Abivax’s blockbuster efficacy readout has been a wild ride for shareholders. After plunging roughly 40% on June 2, the stock recouped more than 16% by Thursday, climbing back toward $105. The whipsaw reflects an intense tug-of-war: stellar Phase 3 results for the oral drug obefazimod in ulcerative colitis, pitted against a small number of cancer cases that have injected fresh uncertainty into the regulatory outlook.
Efficacy delivers on all fronts
The ABTECT maintenance study hit every goal. Patients with moderate-to-severe ulcerative colitis who took 25 mg or 50 mg of obefazimod once daily achieved clinical remission at week 44 at absolute rates of 50.8% and 51.3%, respectively, against a placebo remission rate of just 10.4%. The placebo-adjusted benefit — roughly 39 to 40 percentage points — met a high bar of statistical significance (p<0.0001). All secondary endpoints, including endoscopic improvement, endoscopic remission and sustained clinical remission, were also positive. Abivax noted that the placebo response in ABTECT was among the lowest ever recorded in a Phase 3 maintenance trial for ulcerative colitis, which amplifies the reliability of the efficacy signal.
Skin cancers sour the mood
What sent the stock into a tailspin were four cases of non-melanoma skin cancer reported in the 50-mg group, along with isolated instances of prostate cancer, breast cancer and colonic dysplasia across treated patients. The study investigators assessed the events as not related to treatment, pointing out that the cancer cases occurred in different organ systems with no clustering. The average age of patients who developed skin cancer was 62, well above the trial’s mean age of 42, suggesting age-related risk rather than a drug effect. Despite this, the market fretted that any safety signal — even one deemed unrelated by physicians — could complicate the FDA approval process.
Should investors sell immediately? Or is it worth buying Abivax?
Analysts split down the middle
Wall Street’s reaction reflects the binary nature of the risk. Jefferies downgraded Abivax to “Hold” with a $90 price target, flagging the cancer data as a potential commercial headwind. On the other side, Morgan Stanley and Truist retained more bullish views, setting price targets between $132 and $187, though both raised their risk premiums to account for regulatory uncertainty. Meanwhile, law firms have begun probing whether Abivax adequately disclosed safety risks to shareholders before the data release, a routine development after sharp biotech sell-offs.
Cash runway buys time
Abivax’s balance sheet provides some breathing room. The company reported €491.6 million in cash and short-term investments at the end of March 2026, with working capital exceeding €480 million. Management says that runway extends into the fourth quarter of 2027 — ample to fund the next two critical milestones. The first is a New Drug Application submission to the FDA for obefazimod in ulcerative colitis, planned for late in the fourth quarter of 2026. The second is a Phase 2b induction study in Crohn’s disease, with topline results due by mid-2027.
All eyes now turn to the safety database. The key question is whether the FDA will view the malignancy cases as a meaningful safety signal or accept Abivax’s assessment that they reflect background risk. That decision will likely move the stock far more than the already compelling efficacy data.
Ad
Abivax Stock: New Analysis - 5 June
Fresh Abivax information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
